Floatz logo

L-LYSINAMIDE, L-LYSYL-L-LYSYL-L-TRYPTOPHYL-L-TRYPTOPHYL-L-LYSYL-L-LYSYL-L-TRYPTOPHYL-.BETA.-PHENYL-L-PHENYLALANYL-

Advanced Melanoma

Oslo University Hospitalprotein_peptidePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

449 Active assets in the Advanced Melanoma cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Sargramostim
Mayo Clinic
Phase 3BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Tebentafusp
Immunocore Ltd
Phase 3BB

View all 50 →

Same molecule, other indications

L-LYSINAMIDE, L-LYSYL-L-LYSYL-L-TRYPTOPHYL-L-TRYPTOPHYL-L-LYSYL-L-LYSYL-L-TRYPTOPHYL-.BETA.-PHENYL-L-PHENYLALANYL- is also rated in:

melanomaDormant
CCC
Indicative ·
52 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
head and neck cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →